Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

SML1051

Sigma-Aldrich

Bivalirudin trifluoroacetate salt

≥97% (HPLC)

Sinônimo(s):

D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-aspariginylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl-L-leucine trifluoroacetate, Hirulog trifluoroacetate salt

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C98H138N24O33 · xC2HF3O2
Número CAS:
Peso molecular:
2180.29 (free base basis)
Código UNSPSC:
51111800
NACRES:
NA.77

Ensaio

≥97% (HPLC)

Formulário

powder

cor

white to off-white

Condições de expedição

wet ice

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

N5([C@@H](CCC5)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc6ccc(cc6)O)C(=O)N[C@@H](CC(C)C)C(=O)O)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]2N(CCC2)C(=O)[C@@H](

InChI

1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1

chave InChI

OIRCOABEOLEUMC-GEJPAHFPSA-N

Ações bioquímicas/fisiológicas

Bivalirudin is a specific and reversible bivalent direct thrombin inhibitor.
Bivalirudin is a specific and reversible bivalent direct thrombin inhibitor. Bivalirudin specifically binds to both the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.
Bivalirudin trifluoroacetate salt is a synthetic peptide composed of 20 amino acids. It serves as an anticoagulant for patients with unstable angina undergoing coronary angioplasty.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 3

1 of 3

L-cistina ≥98% (TLC), crystalline

Sigma-Aldrich

C8755

L-cistina

vibrant-m

H0200000

Heparin sodium

Formaldeído ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)

Sigma-Aldrich

252549

Formaldeído

Mahesh V Madhavan et al.
The American journal of cardiology, 114(9), 1322-1328 (2014-09-23)
Postprocedural anticoagulation (AC) after primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) may be administered for a number of specific therapeutic indications (e.g. atrial fibrillation or left ventricular thrombus). However, the safety and effectiveness of such post-PCI
Marco Valgimigli et al.
The New England journal of medicine, 373(11), 997-1009 (2015-09-02)
Conflicting evidence exists on the efficacy and safety of bivalirudin administered as part of percutaneous coronary intervention (PCI) in patients with an acute coronary syndrome. We randomly assigned 7213 patients with an acute coronary syndrome for whom PCI was anticipated
Aakriti Gupta et al.
The American journal of cardiology, 116(1), 1-7 (2015-05-06)
Excess dosing of anticoagulant agents has been linked to increased risk of bleeding after percutaneous coronary intervention (PCI) for women compared with men, but these studies have largely included older patients. We sought to determine the prevalence and gender-based differences
Karolina Szummer et al.
JAMA, 313(7), 707-716 (2015-02-18)
Fondaparinux was associated with reduced major bleeding events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI). Large-scale experience of the use of fondaparinux vs LMWH in
Liquid chromatography method for determination of bivalirudin in human plasma and urine using automated ortho-phthalaldehyde derivatization and fluorescence detection.
Farthing D, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 802(2), 355-359 (2004)

Conteúdo relacionado

We offer agonists, antagonists, modulators and other bioactive small molecules for immune system signaling target identification and validation, as well as a variety of antibiotics, antivirals, and antifungals.

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica